prebiotics-and-probiotics

MEET US - BioActor Presenting MicrobiomeX® and Naxus® at the 15th Annual IPC conference

MEET US – BioActor Presenting MicrobiomeX® and Naxus® at the 15th Annual IPC conference

Maastricht, The Netherlands, June 16th, 2022

Press release
The 15th International Scientific Conference on Probiotics, Prebiotics, Gut Microbiota and Health – IPC2022 will be held during 27 – 30 June 2022 in Bratislava. BioActor is an active contributor and confirmed partner of this conference. Hans van der Saag (CEO) will present on our ingredient Naxus®, a prebiotic with metabolic and immune effects, and Yala Stevens (CSO) presents the clinical and mechanistic research on MicrobiomeX® in irritable bowel syndrome (IBS) patients and elderly subjects.

prebiotics-and-probiotics

BioActor Presenting MicrobiomeX® and Naxus® at the 15th Annual IPC conference

The 15th International Scientific Conference on Probiotics, Prebiotics, Gut Microbiota and Health – IPC2022 will be held during 27 – 30 June 2022 in Bratislava.

The IPC conference is the world’s biggest scientific conference that focuses solely on basic and applied research of probiotics, prebiotics, gut microbiota and health. More than 400 scientists from over more than 80 countries have attended the conference last season.

The scientific program will focus on current advances in the research, production and use of probiotics and prebiotics with particular focus on their role in maintaining health and preventing diseases. At IPC, leading scientists from industry and academia present current advances in understanding and influencing the interaction between gut microbiota and human health.

The conference enables the interactive exchange of state-of-the-art knowledge. It is focused on evidence-based benefits, health claims proven in scientific experiments and clinical trials.

BioActor is an active contributor and confirmed partner of this conference. Hans van der Saag (CEO) will present on our ingredient Naxus®, a prebiotic with metabolic and immune effects, and Yala Stevens (CSO) presents the clinical and mechanistic research on MicrobiomeX® in irritable bowel syndrome (IBS) patients and elderly subjects.

Naxus® presentation by Hans van der Saag (CEO)

Naxus® is a native arabinoxylan extract from the wheat endosperm. It is a powerful and well-tolerated prebiotic with metabolic and immune effects. Due to its complex branched structure, Naxus® is slowly and selectively fermented by multiple species of the microbiota, inducing a remarkable bifidogenic effect without causing gas formation and intestinal discomfort. It induces a remarkable microbiota shift and increased short-chain fatty acids production, with proven effects on immune health and glycemic control.

MicrobiomeX® presentation by Yala Stevens (CSO)

MicrobiomeX® is a natural extract from citrus fruit designed to beneficially modulate the microbiome composition in the gut. It’s a first-in-class Flavobiotic® that protects the gut barrier and directly leverages the gut microbiome’s potential. This results in enhanced immune health, as well as anti-inflammatory effects.

IBS is a functional gastrointestinal disorder with various symptoms including pain and discomfort in the abdomen. Also, elderly often develop imbalances in their gut microbiota and often experience discomfort.

Patients with IBS and elderly would benefit substantially from treatments that could relieve their symptoms and improve their gut health. The flavonoids in MicrobiomeX® have the potential to benefit individuals with gastrointestinal conditions because of its antioxidant and anti-inflammatory properties.

Business opportunities

The IPC conference is a great opportunity to reconnect with colleagues from all over the world and make new contacts. Hans van der Saag (CEO) and Yala Stevens (CSO) will be there to represent BioActor’s portfolio, with a focus on our gut health ingredients. Feel free to pass by at any time to chat about our innovative ingredients for gut health support!

We look forward to meeting you in Bratislava!

The IPC 2022 conference will take place from 27 to 30 June 2022.

Where: Hviezdoslavovo námestie 3, 811 02 Bratislava, Slovakia

About BioActor

BioActor, based in Maastricht, Netherlands, is a product development company that supplies proprietary bioactive formulations to the nutrition & healthcare industry. The company focuses on the development of innovative bioactives that address active living and healthy ageing. The goal is to provide the nutrition & healthcare industry with science-based innovations that confer a real health benefit to the consumer.

For further information, see www.bioactor.com or visit https://microbiomex.com/ or https://naxus.nl/


MicrobiomeX® nominated as finalist for 2022 NutraIngredients-USA ‘Ingredient of the Year’

MicrobiomeX® nominated as finalist for 2022 NutraIngredients-USA ‘Ingredient of the Year’

Maastricht, Netherlands, June 2nd, 2022

Press release
BioActor is delighted to share that MicrobiomeX® was nominated as a finalist for the 2022 NutraIngredients-USA ‘Ingredient of the Year’ in the category Prebiotic. NutraIngredients-USA Awards honour the best and brightest in ingredients, finished products, companies, people and initiatives in the nutrition and dietary supplements industry.

MicrobiomeX-is-a-finalist-for-the-NutraIngredients-Awards

Finalist for 2022 NutraIngredients-USA ‘Ingredient of the Year’

We are excited to announce that MicrobiomeX® was nominated as a finalist for the 2022 NutraIngredients-USA ‘Ingredient of the Year’ in the category Prebiotic.

The NutraIngredients brand has led the online news source in the nutrition industry for over 19 years, providing insights into the functional food and supplement market in North America, ranging from investments and innovation to ingredients, product formulation, regulation, consumer trends and more!

Specifically, NutraIngredients-USA Awards honour the best and brightest in ingredients, finished products, companies, people and initiatives in the nutrition and dietary supplements industry. With a focus on innovation, long-term market success and state-of-the-art research, it is an honour that MicrobiomeX® was nominated a finalist!

MicrobiomeX® is a first-in-class Flavobiotic® that has been clinically proven to improve the SCFA profile, lower gut inflammation and enhance immunity through its precision prebiotic effect. Beneficial changes in the microbiota are induced at a low dose of 250-500 mg, and MicrobiomeX® is stable with probiotics.

“Special thanks goes out to our US distributor SEPPIC with whom we collaborated to get there”, says Joris Kretzers, Sales Manager Western Europe & North America of BioActor. “We are very proud of this achievement and are looking forward to the winner announcement in July!”

About BioActor

BioActor, based at the Maastricht Health Campus, Netherlands, is a life science company that has developed a range of proprietary bioactive ingredients for the nutrition & consumer health industries. The company focuses on the development of plant-based health ingredients for active living and healthy ageing. The goal is to provide the nutrition & consumer health industries with clinically tested innovations that confer a real health benefit to the consumer.

Feel free to contact BioActor via info@bioactor.com for more information on the possibilities MicrobiomeX® has to offer.

Further information can be found on:  www.microbiomex.com and www.bioactor.com


Can-Prebiotics-and-Probiotics-help-relieve-IBS-symptoms?

Can Prebiotics and Probiotics help relieve IBS symptoms?

Can Prebiotics and Probiotics help relieve IBS symptoms?

May 19th, 2022

Prebiotics and probiotics are an interesting topic for people with gastrointestinal disorders, including irritable bowel syndrome (IBS). Researchers have conducted various studies regarding their influence on improving IBS symptoms. In this article, we will explain the different types of IBS and how prebiotics and probiotics may be beneficial in managing this chronic long-term condition.

Can-Prebiotics-and-Probiotics-help-relieve-IBS-symptoms?

What is IBS?

Irritable bowel syndrome (IBS) is a chronic condition that affects the quality of people’s lives and includes symptoms such as abdominal pain or discomfort, bloating, gas, constipation, and diarrhea [1].

Some studies have estimated that more than 9% of the worldwide population suffers from IBS, with women 1.5 to 3 times more likely to experience IBS symptoms [2].

To date, IBS causes are still unknown and some possible factors that are responsible for IBS, include physiological disturbances, genetics, and digestive motility [3]. Based on the abnormal manifestation of the bowel movements, IBS has four subtypes [4, 5].

  1. IBS-C: Constipation prevailing
  2. IBS-D: Diarrhea predominant
  3. IBS-M: Mixed of Constipation and Diarrhea
  4. IBS-U: Unspecified when a patient does not belong to one of these categories

Probiotics and IBS

Although the causes of IBS are still unknown, it has been suggested that an imbalance of the gut microbiota can be responsible for IBS development.

Probiotics are live microorganisms that confer a health benefit on the host by decreasing the harmful bacteria and supporting the gut’s natural bacteria [6]. If you want to increase the good bacteria in your body, various fermented foods and supplements include probiotics.

As it concerns food, a few suggestions might be yoghurt, tempeh, kombucha and kimchi , while supplements usually include beneficial strains like Saccharomyces Boulardii, Bifidobacterium Bifidum, Bifidobacterium Lactis, Lactobacillus Acidophilus, and Lactobacillus Plantarum.

Research has shown that IBS symptoms can be improved by the daily consumption of Probiotics, even if the exact mechanism is still not completely understood [7]. Probiotics can act in different ways depending on the type of IBS and other factors such as age and gender [8].

It is proposed that Probiotics may improve IBS symptoms by [9]:

• Inhibiting the colonisation of pathogens in the gut
• Enhancing the gut barrier function
• Boosting the immune system
• Improving digestive functions
• Reducing inflammation in the gut and gas formation

Prebiotics and IBS

Prebiotics are usually non-digestible fibre compounds that are fermented by the gut microbiota, stimulating the growth and/or activity of beneficial bacteria (probiotics) in the gut [10]. To classify these compounds as prebiotics, they need to comply with three requirements [11]:

• be non-digestible and resistant to breakdown by stomach acid and enzymes in the human gastrointestinal tract
• be fermented by living microorganisms in the gut
• stimulate the growth and/or activity of beneficial bacteria (probiotics)

Research into the role of prebiotics in managing IBS symptoms is conflicting and shows that the beneficial effect may be subjective and depend on the IBS and type.

For example, some studies found that soluble fibres such as psyllium and inulin may provide significant pain relief for IBS patients with constipation and/or diarrhoea. In contrast, other studies found that the effect is limited.

Prebiotics act by stimulating the growth of a bacterium that produces lactic acid called Bifidobacterium. Interestingly, Bifidobacterium has been associated with improved gastrointestinal symptoms in people with IBS. More specifically, this genus lowers the pH to desirable levels for beneficial microbes and undesirable levels for pathogenic bacteria
[12].

The consumption of specific prebiotics such as arabinoxylans from wheat (AX) can increase the amount of Bifidobacterium in the colon.

In addition, there are also molecules with known prebiotic activity, such as citrus-derived flavonoids. Research has shown that these compounds can reach the colon without being digested and are metabolised by the gut microbiota, stimulating the growth of beneficial bacteria..

These prebiotic flavonoids are different from prebiotic fibres because they are not fermented but rather deglycosylated by the gut microbiota. Furthermore, their ability to work at low doses is associated with their high tolerance as opposed to fibres. Finally, the lack of fermentation avoids gas formation and the resulting feeling of bloating and flatulence.

Multiple studies have shown better protection of gut mucosa against colonisation by pathogens and viruses. Also, citrus flavonoids allow greater production of Short Chain Fatty Acids (SCFA) like butyrate and propionate, important compounds for the immune system and metabolic functions.

The bottom line

IBS is a chronic condition that affects a large part of the world’s population.

There is no known cure for this condition, but there are many treatment options to reduce or eliminate symptoms, such as dietary modifications, lifestyle changes, and prescription medications.

In many cases, probiotics and prebiotics may be beneficial in managing the IBS symptoms. However, the beneficial effect is subjective and depends on the IBS type. Therefore, it is essential to understand how dietary changes and supplementations affect the symptoms.


BioActor-is-participating-in-Vitafoods-2022-meet-us-Booth-F140

MEET US - Vitafoods Europe 2022

Visit us at Vitafoods Europe 2022

April 22nd, 2022

We are happy to announce that BioActor will participate in Vitafoods 2022, the trade show that offers the opportunity to find out the latest trends in the field of dietary supplements, raw materials, and food and to network with other professionals from around the world. Visit us at Booth F140.

BioActor-is-participating-in-Vitafoods-2022-meet-us-Booth-F140

Meet us at Booth F140

Our team can’t wait to meet you online from May 2nd to May 13th, and in Geneva from May 10th to 12th.

You are welcome to come over for a coffee at our booth F140 to discuss new business opportunities and get an idea of how our science-based ingredient can help you achieve your product development goals.

Amongst the most exciting news, our team will be happy to present the recently concluded randomized clinical trials on our gut health and brain fitness solutions, MicrobiomeX® and Brainberry®.

Don’t miss it, we are looking forward to seeing you there!

Book a meeting!



    New-in-vitro-co-culture-model-study-published-with-citrus-flavonoid-extract

    New in vitro co-culture model study published with citrus flavonoid extract MicrobiomeX®

    New in vitro co-culture model study published with citrus flavonoid extract MicrobiomeX®

    Maastricht, Netherlands, April 21st, 2022

    Press release
    British Journal of Nutrition has recently published a new in vitro co-culture model study with a citrus flavonoid extract MicrobiomeX® and its metabolites, hesperetin and naringenin. The novel publication suggests that these citrus flavonoids, as well as their metabolites, may reduce intestinal inflammation.

    New-in-vitro-co-culture-model-study-published-with-citrus-flavonoid-extract

    New in vitro co-culture model study published with citrus flavonoid extract MicrobiomeX®

    MicrobiomeX® is a first-in-class Flavobiotic® developed by BioActor, that combines active ingredients from Citrus sinensis and Citrus paradisi. MicrobiomeX® has already been studied and reported to have various beneficial effects on the gut and immunity. MicrobiomeX® consists of standardised citrus flavonoids, that form active metabolites, hesperetin and naringenin, in the gut after being deglycosylated by the gut microbiota.

    In the recently published in-vitro study, a validated co-culture system of Caco-2/THP-1 cells as model for intestinal inflammation and cytokine-induced barrier disruption was used to determine the effects of citrus flavonoids and their metabolites on intestinal inflammation.

    During the research, cells were treated with citrus flavonoids, their metabolites, or a vehicle control. Additionally, cells were incubated with lipopolysaccharide (LPS), which is known to induce inflammation and deterioration in epithelial integrity.

    The conclusion highlights that hesperetin and naringenin significantly reduced NF-kB activity, leading to a reduction in intestinal inflammation. Pro-inflammatory cytokines IL-8, TNF-α and IL-6 were also significantly reduced after hesperetin and naringenin administration.

    The mechanism behind this reduction in inflammation can be ascribed to partial inhibition of the NF-κB signalling pathway.

    “We are very happy with the results of this study, as we were able to show that both the citrus flavonoids themselves and their metabolites are able to reduce inflammation in the intestine”, says Yala Stevens, CSO of BioActor. “These new scientific insights on MicrobiomeX® will allow us to consolidate its applications to products targeting gut health and immune function”.

    About BioActor

    BioActor, based at the Maastricht Health Campus, Netherlands, is a life science company that has developed a range of proprietary bioactive ingredients for the nutrition & consumer health industries. The company focuses on the development of plant-based health ingredients for active living and healthy ageing. The goal is to provide the nutrition & consumer health industries with clinically tested innovations that confer a real health benefit to the consumer.

    Feel free to contact BioActor via info@bioactor.com for more information on the possibilities MicrobiomeX® has to offer.

    Further information can be found on:  www.microbiomex.com and www.bioactor.com


    Microbiomex supports immunity

    Three ways MicrobiomeX® supports your immune system

    Three ways MicrobiomeX® supports your immune system

    March 25th, 2022

    The knowledge about gut microbiota and its connection with the immune system is increasing every day and so is the consumption of science-based products helping consumers achieve their immunity goals. MicrobiomeX® is a nutraceutical ingredient based on citrus flavonoids that can boost your immune system by improving the gut microbiota composition stimulating the production of butyrate, increasing the level of antibody SIgA, and lowering the level of intestinal inflammation.

    Microbiomex supports immunity

    The connection between gut microbiota and immune system

    Every day the body is exposed to different pathogens that can potentially cause disease. The immune system can protect the body from these intruders and the gut microbiota plays a crucial role in doing so.

    The microbiome consists of a collection of bacteria living in your gut. Primarily, the good bacteria residing in the intestine adhere to the gut wall. Once the gut wall is full of these bacteria, other pathogens cannot adhere. In this way, beneficial bacteria prevent bad bacteria from “sticking” to the gut mucosa [1].

    Moreover, these bacteria produce important molecules such as short-chain fatty acids (SCFA) that are involved in improving immune function and lowering gut inflammation.

    What is MicrobiomeX®?

    MicrobiomeX® is an ingredient based on citrus flavonoids that can boost the immune system and improve gut defense.

    BioActor developed MicrobiomeX® and, together with Maastricht University and Wageningen University, researched the ingredient and confirmed its health benefits in multiple clinical, ex-vivo and in-vitro studies.

    Clinical research in different study populations has shown that MicrobiomeX® has a direct effect on gut health and immunity by being metabolized by gut microbiota and positively changing the microbiota composition. This is what we call Flavobiotic® effect.

    MicrobiomeX® is standardize for two important citrus flavonoids: hesperidin (>85%) and naringin (>5%)

    The Flavobiotic® effect and immune boosting effects have been demonstrated at low dose from 250mg to 500mg in a dose dependent fashion.

    Three ways MicrobiomeX® supports your immune system

    If you are considering including MicrobiomeX® in your formulation, you should know this:

    1. MicrobiomeX® positively changes the microbiota composition helping stimulate the production of butyrate.

    When health-promoting bacteria are present in the gut, they help protect your gut wall from pathogens and bad microorganisms. MicrobiomeX® has been shown to help the growth of beneficial microbiota in the gut, for example strains that belong to the phylum Firmicutes.

    Not only helps MicrobiomeX® with maintaining a protective layer against bad microorganisms, but it also promotes butyrate-producing strains such as Faecalibacterium prausnitzii, Clostridium leptum and Roseburia. This results in higher levels of butyrate [2].

    This is beneficial, mainly because butyrate inhibits nuclear factor κB (NF-κB). Dysregulation of NF-κB is often seen in inflammatory bowel diseases, such as Crohn’s disease and ulcerative colitis. This means, that by increasing butyrate levels in the gut and consequently inhibiting NF-κB MicrobiomeX® helps lower inflammation in the gut [3].

     

    2. MicrobiomeX® increases Secretory Immunoglobulin A

    After four weeks of daily 500 mg MicrobiomeX®, fecal Secretory Immunoglobulin A (SIgA) significantly increased in healthy elderly.

    Why is this good news?

    IgA is the antibody that is the most produced by the body and it is primarily found in the gastrointestinal system, where it plays a big role in keeping your intestinal microbiota in check. IgA directly binds to pathogens such as bad bacteria and viruses and neutralizes them.

    Neutralization of pathogens stops them from colonizing the mucosal layer of the gut wall and infiltrating the cells of the gut to cause illness. This protection mechanism is known as ‘immune exclusion’ and makes SIgA a key factor in your immune system.

    SigA activation and gut function

    3. MicrobiomeX® lowers gut inflammation

    Consumption of MicrobiomeX has shown to lower calprotectin levels. Calprotectin is found in different parts of the body, and it is an indicator of chronic inflammation.

    Typically, older people and people with irritable bowel syndrome or leaky gut syndrome have chronically increased levels of calprotectin [4].

    Gut inflammation leads to a lesser functioning gut barrier, which makes it easier for pathogens to infiltrate your body. MicrobiomeX® has been shown to decrease fecal calprotectin, indicating it lowers gut inflammation and thus, your gut health benefits from this product.

    Moreover, MicrobiomeX® was shown to be able to lower NF-κB levels in a co-culture study with Caco-2 cells line and macrophages. NF-κB is a proinflammatory transcription factor involved in the production of inflammatory chemokine such as TNF-a, which accordingly was shown decreased in the same study.

    The bottom line

    There are several ways your gut helps to fight against pathogens that cause disease. It is good to boost your immune system and the citrus flavonoids in MicrobiomeX® offer a way to support your immune system naturally.


    New Publication in Nutrients shows beneficial effects of MicrobiomeX® in TIM-2 model

    New Publication in Nutrients shows beneficial effects of MicrobiomeX® in TIM-2 model

    Maastricht, The Netherlands, 17th November 2021

    Press release
    The effect of MicrobiomeX®, a natural citrus ingredient consisting of specific active flavonoids, was evaluated through in-vitro examination in the TIM-2 model. The study results, recently published in a peer-reviewed journal, showed that MicrobiomeX® can beneficially change the microbiota composition and Short-Chain Fatty Acids production of human volunteers.

    In-Vitro Study on MicrobiomeX®

    A recent in-vitro study in the TIM-2 dynamic model of the large intestine has shown that MicrobiomeX® has a profound effect on the microbiota composition, already after three days.

    MicrobiomeX® is a natural Flavobiotics® from citrus fruits, designed to support gut & immune health by lowering gut inflammation and beneficially shifting the gut microbiome composition.

    This innovative flavonoid-based ingredient has already shown in a first clinical trial to boost overall gut health by positively changing the short-chain fatty acid composition. In addition, lower faecal calprotectin levels (an important biomarker of gut inflammation) were found in the treatment group.

    The outcome of the new in-vitro study, recently published in Nutrients, showed that the consumption of MicrobiomeX® led to a microbiota composition typical of a person following a healthy plant-based diet rich in fibre.

    The study was conducted by the group of Professor Koen Venema, who is also the last author of the publication.

    The purpose of the study was to find out whether low doses of MicrobiomeX® – 250mg and 350mg – would have a short term effect on the human gut microbiota and the production of short-chain fatty acids.

    The study was carried out in the TIM-2 model with faecal samples from 7 human volunteers. These samples were either treated with two different doses of MicrobiomeX® or a control. Already after 48 hours, the first differences between the treatment and the control could be observed, which became significant after 72 hours.

    Interestingly, a potent butyrate-producing class of bacteria – Roseburia spp – was significantly increased with both the 250mg and the 350mg doses, whereby the increases were clearly dose-dependent.

    Click here to download the complete publication.

    About BioActor

    BioActor, based in Maastricht, Netherlands, is a product development company that has developed a range of proprietary bioactive ingredients for the nutrition & healthcare industry. The company focuses on the development of innovative activities that address active living and healthy ageing. The goal is to provide the nutrition & healthcare industry with science-based innovations that confer a real health benefit to the consumer.

    Feel free to contact us for more information on the possibilities MicrobiomeX® has to offer.

    Further information can also be found on: www.microbiomex.com


    microbiomex systematic review

    Clinical and pre-clinical data on MicrobiomeX® now published in a peer-reviewed journal

    Clinical and pre-clinical data on MicrobiomeX® now published in a peer-reviewed journal

    Maastricht, The Netherlands, July 11th, 2019

    Press release
    Nutrients, peer-reviewed journal of human nutrition, has published a systematic review on ‘flavobiotics’ – citrus flavonoids – and their effects on the microbiota and gastrointestinal health. The review includes original research data obtained with MicrobiomeX®. MicrobiomeX® is a natural citrus flavonoid complex designed to support gut and immune health, by lowering gut inflammation and beneficially shifting the gut microbiome composition.

    microbiomex systematic review

    The Systematic Review of MicrobiomeX®

    Nutrients have published a systematic review on ‘flavobiotics’ – citrus flavonoids – and their effects on gastrointestinal health. The review includes original in-vitro and in-vivo data on MicrobiomeX®.

    MicrobiomeX® is a first-in-class Flavobiotic® that protects the gut barrier and directly leverages the gut microbiome’s potential, enhancing the immune system. MicrobiomeX® is standardized for the two active citrus flavonoids: Hesperidin and Naringin.

    The purpose of this systemic review article on citrus flavonoids and gut health was to provide a detailed overview of the intestinal metabolism of citrus flavonoids, their interaction with the gut microbiota composition, and their positive effect on the host barrier function and gut inflammation.

    The review article also includes the outcomes of a 12-week randomized, parallel, double-blind, placebo-controlled study in which the effect of MicrobiomeX® on the gut microbiome composition, short-chain fatty acid production and gut inflammation was assessed. The study was conducted in a group of 50 healthy subjects with overweight, low background chronic gut inflammation and a somewhat disturbed microbiota.

    The results showed
    MicrobiomeX® anti-inflammatory activity as a result of a cross-talk between the active citrus flavonoids and the gut microbiome composition. Indeed, a significant increase in the butyrate proportion of total SCFA was measured, and an almost significant reduction in calprotectin levels are signs of the positive contribution of MicrobiomeX® to a balanced microbiome and host gut health.

    MicrobiomeX® can already be found as a stand-alone ingredient or in combination with different probiotic strains, in several products worldwide. It can be applied in various finished dosage forms, including capsules, tablets, RTD sachets and beverages. MicrobiomeX® is the ideal candidate to bring cutting edge science from the microbiome revolution to nutritional formulas.

    About BioActor

    BioActor, based in Maastricht, Netherlands, is a product development company that has developed a range of proprietary bioactive ingredients for the nutrition & healthcare industry. The company focuses on the development of innovative activities that address active living and healthy ageing. The goal is to provide the nutrition & healthcare industry with science-based innovations that confer a real health benefit to the consumer.

    Feel free to contact us for more information on the possibilities MicrobiomeX® has to offer.

    Further information can also be found on: www.microbiomex.com


    Yakult Korea launched a new synbiotic food product ‘MPRO3’with MicrobiomeX® for intestinal health.

    Yakult Korea launched a new synbiotic food product ‘MPRO3’with MicrobiomeX® for intestinal health.

    Maastricht, The Netherlands, March 05, 2019

    Press release
    Extensive research studies on the natural flavonoids found in MicrobiomeX® has shown to work in synergy with prebiotics and probiotics to enhance intestinal health. Therefore, MicrobiomeX® was incorporated within one of Yakult’s new products ‘MPRO3’ in Korea.

    Incorporation of MicrobiomeX® into ‘MPRO3’

    Yakult Korea, one of the leading functional food manufacturers in Korea, has introduced a new dual-function intestinal health care food product ‘MPRO3’ with MicrobiomeX®in the Korean market.

    After extensive research, encapsulated probiotics and liquid prebiotics were packed in a MPRO3 bottle. ‘Probiotics’, MicrobiomeX® and ‘Prebiotics’ work together in a synergistic way to enhance the health function of the intestine. Probiotic content of the MPRO3 created, using three kinds of patented lactic acid bacteria.

    MicrobiomeX® is a natural ingredient from citrus, consisting of specific active flavonoids. It has a unique dual mode of action, whereby the flavonoids are firstly acting as a substrate for specific butyrate producing microbes in the gut and thus improving the gut microbiome composition and enhancing the gut barrier. Secondly, the active -metabolized- flavonoids of MicrobiomeX® lower the gut inflammation and support the immune system.

    A first-in-class flavobiotic®, MicrobiomeX® optimizes digestive health and enhances the immune system!

    About BioActor

    BioActor, based in Maastricht, Netherlands, is a product development company that has developed a range of proprietary bioactive ingredients for the nutrition & healthcare industry. The company focuses on the development of innovative activities that address active living and healthy aging. The goal is to provide the nutrition & healthcare industry with science-based innovations that confer a real health benefit to the consumer.

     

    Feel free to contact us via info@bioactor.com for more information on the possibilities MicrobiomeX® has to offer.
    Further information can be found on: www.microbiomex.com


    New Open label Study MicrobiomeX® on intestinal health & well-being in triathlon athletes.

    New Open label Study MicrobiomeX® on intestinal health & well-being in triathlon athletes.

    Maastricht, The Netherlands, November 26th, 2018

    Press release

    Bioactor’s already clinically studied product MicrobiomeX® has gone through a new open label study in triathlon athletes. Within only 6 weeks of 50omg of MicrobiomeX®, showed less exhaustion in performance, an improved gut health and an overall decrease in health complaints.

    The open Label Study

    Citrus flavonoids are known for their antioxidant capacity and their ability to suppress inflammation. Hesperidin and naringin are two important flavonoids from citrus fruit and previous studies showed their anti-inflammatory and antioxidant capacity.

    BioActor developed Microbiomex®, a first in class ingredient standardized for the most active forms of flavonoids from citrus. An earlier clinical study in overweight subjects showed reduced fecal calprotectin levels and a significant increase of butyrate levels, reducing inflammation.

    Gastrointestinal complaints are very common in triathlon athletes due to physical stress, resulting in underperformance as well as reduced recovery after physical activity. One of the main contributors of exercise related gastrointestinal complaints is the reduction in mesenteric blood flow during high level physical activity, resulting in an impaired function of the gut barrier.

    BioActor conducted a new open label study with MicrobiomeX®, in triathlon athletes. The objectives of this new open label study were to investigate any changes in exercise performance, gut health and wellbeing in 15 trained athletes. After 6 weeks of 500 mg MicrobiomeX® consumption the participants felt healthier, less restricted by their health complaints and their gut health was improved. In addition, they felt more vigorous and energetic, and less exhausted and tired during the day.

     

    About BioActor

    BioActor, based in Maastricht, Netherlands, is a product development company that has developed a range of proprietary bioactive ingredients for the nutrition & healthcare industry. The company focuses on the development of innovative activities that address active living and healthy aging. The goal is to provide the nutrition & healthcare industry with science-based innovations that confer a real health benefit to the consumer.

    Feel free to contact us via info@bioactor.com for more information on the possibilities MicrobiomeX® has to offer.
    Further information can be found on: www.microbiomex.com